Higher dose of Novartis drug Exelon® Patch approved by FDA for patients with mild to moderate Alzheimer's disease
21:32 EDT 3 Sep 2012 | PR Newswire
This article has expired, however you can still
download the PDF.
Preview:
EAST HANOVER, N.J., Sept. 4, 2012 /PRNewswire/ -- The US Food and Drug Administration has approved a higher dose of Exelon® Patch (rivastigmine transdermal system) for the treatment of people with mild to moderate Alzheimer's disease. The new 13....
Other Sources for this Article
More From BioPortfolio on "Higher dose of Novartis drug Exelon® Patch approved by FDA for patients with mild to moderate Alzheimer's disease"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
